<VariationArchive RecordType="classified" VariationID="15958" VariationName="NM_000516.7(GNAS):c.1097_1108dup (p.Thr369_Glu370insAlaValAspThr)" VariationType="Duplication" Accession="VCV000015958" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-12-25" DateCreated="2016-08-22" MostRecentSubmission="2016-08-22">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="30997" VariationID="15958">
      <GeneList>
        <Gene Symbol="GNAS" FullName="GNAS complex locus" GeneID="2778" HGNC_ID="HGNC:4392" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>20q13.32</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="58839748" stop="58911192" display_start="58839748" display_stop="58911192" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="57414794" stop="57486249" display_start="57414794" display_stop="57486249" Strand="+" />
          </Location>
          <OMIM>139320</OMIM>
          <Haploinsufficiency last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GNAS">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GNAS">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000516.7(GNAS):c.1097_1108dup (p.Thr369_Glu370insAlaValAspThr)</Name>
      <CanonicalSPDI>NC_000020.11:58910739:GCTGTGGACACTG:GCTGTGGACACTGCTGTGGACACTG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>20q13.32</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="58910739" stop="58910740" display_start="58910739" display_stop="58910740" variantLength="12" positionVCF="58910739" referenceAlleleVCF="C" alternateAlleleVCF="CGCTGTGGACACT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="57485794" stop="57485795" display_start="57485794" display_stop="57485795" variantLength="12" positionVCF="57485794" referenceAlleleVCF="C" alternateAlleleVCF="CGCTGTGGACACT" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.10" sequenceAccession="NC_000020" sequenceVersion="10" change="g.57485796_57485807dup" Assembly="GRCh37">
            <Expression>NC_000020.10:g.57485796_57485807dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.11" sequenceAccession="NC_000020" sequenceVersion="11" change="g.58910741_58910752dup" Assembly="GRCh38">
            <Expression>NC_000020.11:g.58910741_58910752dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_016194.2" sequenceAccession="NG_016194" sequenceVersion="2" change="g.76002_76013dup">
            <Expression>NG_016194.2:g.76002_76013dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000516.7" sequenceAccession="NM_000516" sequenceVersion="7" change="c.1097_1108dup" MANESelect="true">
            <Expression>NM_000516.7:c.1097_1108dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000507.1" sequenceAccession="NP_000507" sequenceVersion="1" change="p.Thr369_Glu370insAlaValAspThr">
            <Expression>NP_000507.1:p.Thr369_Glu370insAlaValAspThr</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077488.5" sequenceAccession="NM_001077488" sequenceVersion="5" change="c.1100_1111dup">
            <Expression>NM_001077488.5:c.1100_1111dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001070956.1" sequenceAccession="NP_001070956" sequenceVersion="1" change="p.Thr370_Glu371insAlaValAspThr">
            <Expression>NP_001070956.1:p.Thr370_Glu371insAlaValAspThr</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077489.4" sequenceAccession="NM_001077489" sequenceVersion="4" change="c.1052_1063dup">
            <Expression>NM_001077489.4:c.1052_1063dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001070957.1" sequenceAccession="NP_001070957" sequenceVersion="1" change="p.Thr354_Glu355insAlaValAspThr">
            <Expression>NP_001070957.1:p.Thr354_Glu355insAlaValAspThr</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001077490.3" sequenceAccession="NM_001077490" sequenceVersion="3" change="c.*958_*969dup">
            <Expression>NM_001077490.3:c.*958_*969dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001309840.2" sequenceAccession="NM_001309840" sequenceVersion="2" change="c.920_931dup">
            <Expression>NM_001309840.2:c.920_931dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001296769.1" sequenceAccession="NP_001296769" sequenceVersion="1" change="p.Thr310_Glu311insAlaValAspThr">
            <Expression>NP_001296769.1:p.Thr310_Glu311insAlaValAspThr</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001309861.2" sequenceAccession="NM_001309861" sequenceVersion="2" change="c.920_931dup">
            <Expression>NM_001309861.2:c.920_931dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001296790.1" sequenceAccession="NP_001296790" sequenceVersion="1" change="p.Thr310_Glu311insAlaValAspThr">
            <Expression>NP_001296790.1:p.Thr310_Glu311insAlaValAspThr</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_016592.5" sequenceAccession="NM_016592" sequenceVersion="5" change="c.*1003_*1014dup" MANEPlusClinical="true">
            <Expression>NM_016592.5:c.*1003_*1014dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_080425.4" sequenceAccession="NM_080425" sequenceVersion="4" change="c.3026_3037dup" MANEPlusClinical="true">
            <Expression>NM_080425.4:c.3026_3037dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_536350.2" sequenceAccession="NP_536350" sequenceVersion="2" change="p.Thr1012_Glu1013insAlaValAspThr">
            <Expression>NP_536350.2:p.Thr1012_Glu1013insAlaValAspThr</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_080426.4" sequenceAccession="NM_080426" sequenceVersion="4" change="c.1055_1066dup">
            <Expression>NM_080426.4:c.1055_1066dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_536351.1" sequenceAccession="NP_536351" sequenceVersion="1" change="p.Thr355_Glu356insAlaValAspThr">
            <Expression>NP_536351.1:p.Thr355_Glu356insAlaValAspThr</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="139320.0035" DB="OMIM" />
        <XRef Type="rs" ID="2146305803" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000516.7(GNAS):c.1097_1108dup (p.Thr369_Glu370insAlaValAspThr) AND Pseudohypoparathyroidism" Accession="RCV000017328" Version="24">
        <ClassifiedConditionList TraitSetID="5179">
          <ClassifiedCondition DB="MedGen" ID="C0033806">Pseudohypoparathyroidism</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2007-10-30" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2007-10-30" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2016-08-22" MostRecentSubmission="2016-08-22">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11073544</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17962410</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="5179" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3403" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pseudohypoparathyroidism</ElementValue>
                <XRef ID="HP:0000852" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0019992" DB="MONDO" />
                <XRef ID="58976002" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHP1A</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.</Attribute>
                <XRef ID="NBK459117" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10758" />
                <XRef ID="10758" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29072892</ID>
                <ID Source="BookShelf">NBK459117</ID>
              </Citation>
              <XRef ID="79443" DB="Orphanet" />
              <XRef ID="97593" DB="Orphanet" />
              <XRef ID="C0033806" DB="MedGen" />
              <XRef ID="MONDO:0019992" DB="MONDO" />
              <XRef Type="primary" ID="HP:0000852" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="37600" SubmissionDate="2016-08-05" DateLastUpdated="2016-08-22" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="139320.0035_PSEUDOHYPOPARATHYROIDISM, TYPE IA" title="GNAS, 12-BP INS, NT1107_PSEUDOHYPOPARATHYROIDISM, TYPE IA" />
        <ClinVarAccession Accession="SCV000037600" DateUpdated="2016-08-22" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2007-10-30">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a brother and sister with a PHP Ia phenotype (103580), who also had neonatal diarrhea and pancreatic insufficiency, Aldred et al. (2000) identified heterozygosity for a 12-bp insertion in exon 13 of the GNAS1 gene, resulting in an in-frame ala-val-asp-thr (AVDT) repeat at codon 366 within the beta-6/alpha-5 loop. The mutation was not found in 2 unaffected sibs and was also not detected in the lymphocyte DNA of either of the clinically unaffected parents. Haplotype analysis confirmed germline mosaicism and indicated that the mutation was maternal in origin.</Attribute>
              <Citation>
                <ID Source="PubMed">11073544</ID>
              </Citation>
              <XRef DB="OMIM" ID="103580" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">By biochemical and intact cell analysis of the mutant Gs-alpha containing the AVDT repeat within its GDP/GTP binding site, Makita et al. (2007) demonstrated that the mutant protein was unstable but constitutively active as a result of rapid GDP release and reduced GTP hydrolysis, suggesting that instability and paradoxical inactivation by receptor stimulation results in a loss of function. Gs-alpha-AVDT was located primarily in the cytosol except in rat and mouse small intestine epithelial cells, where it was found predominantly in the membrane, with adenylyl cyclase present and constitutive increases in cAMP accumulation occurring in parallel. Makita et al. (2007) suggested that the PHP Ia phenotype results from the instability of the Gs-alpha-AVDT mutant and that the accompanying neonatal diarrhea may result from its enhanced constitutive activity in the intestine.</Attribute>
              <Citation>
                <ID Source="PubMed">17962410</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNAS" />
          </GeneList>
          <Name>GNAS, 12-BP INS, NT1107</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">12-BP INS, NT1107</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="139320.0035" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">PSEUDOHYPOPARATHYROIDISM, TYPE IA</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="37600" TraitType="Disease" MappingType="Name" MappingValue="PSEUDOHYPOPARATHYROIDISM, TYPE IA" MappingRef="Preferred">
        <MedGen CUI="C3494506" Name="Pseudohypoparathyroidism type I A" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

